Overview

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab
Capecitabine
Oxaliplatin